{"id":"W3022175316","doi":"10.1038/s41388-020-1301-9","title":"Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma","year":2020,"lang":"en","type":"article","venue":"Oncogene","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Ontario Genomics; Ontario Ministry of Research, Innovation and Science; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Deutsche Forschungsgemeinschaft; Wellcome Trust; Novartis Pharma; Deutschen Konsortium für Translationale Krebsforschung; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; Merck KGaA; Deutsche Krebshilfe; Pfizer","keywords":"BRD4; Bromodomain; BET inhibitor; Biology; Cancer research; Epigenetics; Oncogene; Acetylation; Histone; Cell cycle; Cancer; Molecular biology; Gene; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006527976,0.00008591346,0.0001241624,0.000009399559,0.00003778535,0.000003373224,0.00009967745,0.00005223547,0.00001870461],"category_scores_gemma":[0.00002245275,0.00005667622,0.0001232473,0.00005133255,0.00004712497,0.000001239251,0.00001663147,0.00001433924,0.000001098365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008434957,"about_ca_system_score_gemma":0.00004230873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001287406,"about_ca_topic_score_gemma":0.000004552666,"domain_scores_codex":[0.9994877,0.00002691234,0.0001807715,0.0001415738,0.00006657655,0.00009646799],"domain_scores_gemma":[0.9996331,0.00001897845,0.0001015922,0.0001544355,0.00005660476,0.00003529017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001383665,0.00007420807,0.0007824845,0.00001802581,0.00006152533,2.603957e-7,0.000148421,0.00001921953,0.9878467,0.00006367605,0.0005289212,0.01031815],"study_design_scores_gemma":[0.0007423236,0.0009790431,0.0001725513,0.000002600715,0.00002581239,5.901279e-7,0.0001071244,0.0001723618,0.8812031,0.00002759982,0.1165123,0.00005463352],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814194,0.01011789,0.005866265,0.001820624,0.00008481564,0.0004460414,0.00005781613,0.000004770366,0.0001823779],"genre_scores_gemma":[0.9969184,0.0003560813,0.001877096,0.0002645602,0.0002855787,0.00003843396,0.00008943486,0.00001233814,0.0001580086],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1159834,"threshold_uncertainty_score":0.2311189,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02589990274909979,"score_gpt":0.264227625750276,"score_spread":0.2383277230011762,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}